Cardiac Ablation Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Cardiac Ablation Market in 2025 is estimated at USD 4.28 billion. The global Market size surpassed USD 3.86 billion in 2024 and is projected to witness a CAGR of over 13.7%, crossing USD 20.49 billion revenue by 2037. North America is set to cross largest share by 2037, owing to high prevalence of heart disease and the presence of key pharmaceutical companies.
The growth of the market can be attributed to growing consumption of alcohol, tobacco and substance abuse which is further boosting the prevalence for cardiac ailments. According to a new brief released by the World Health Organization, the World Heart Federation, and the University of Newcastle Australia ahead of World Heart Day, which is observed on September 29, 1.9 million people per year pass away from tobacco-induced heart disease.
Smoking and the consumption of any other substances greatly affect the functioning of the heart, along with all other body parts. According to the FDA, the poisonous mixture of more than 7,000 chemicals in cigarette smoke could interfere with vital bodily functions when it is inhaled, causing serious health problems. Getting oxygen-rich blood to the heart and the rest of the body is one of processes of inhaling. When a person breathes, the lungs receive oxygen and send it to the heart, which then circulates this blood throughout the rest of the body via the blood arteries. In addition, when people inhale cigarette smoke, the blood that is circulated to the rest of the body picks up the compounds in the smoke. These substances could harm the blood vessels and heart, which could result in cardiovascular disease (CVD) or other heart disease.
Cardiac Ablation Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Diabetes Mellitus - The expected prevalence of diabetes worldwide in 2019 was about 8% (approximately 460 million people), and it was predicted to increase to about 9% (approximately 570 million) by 2030 and more than 11% (approximately 699 million) by 2045. Atrial fibrillation (AF) cardiac ablation appears to be a safe therapy in people with diabetes mellitus (DM) and considerably lowers symptom load in this group. Patients with and without DM experienced comparable post-procedural complications and hospitalization rates. Hence, owing to this, the cardiac ablation market is estimated to boost over the forecast period.
- Rising Geriatric Population - According to the World Health Organization, the number of people 60 and older in the world is expected to double by 2050 (2.1 billion). One of the key elements that is going to have a beneficial effect on cardiac ablation market revenue is the growing geriatric demographic base. The number of ablation treatments would increase in the coming years since elderly people to experience a greater variety of cardiovascular problems than younger people. Moreover, age-related changes in the heart's and blood vessels' functionality increase the risk of cardiac diseases. Additionally, the ageing population is projected to fuel the need for cardiac ablation as it is a safe and highly successful treatment for disorders such as atrial fibrillation, arrhythmia, and tachycardia.
- Surge in Investment in the Healthcare Sector - Throughout the past two decades, India has emerged as one of the fastest-growing emerging economies, benefiting from significant FDI inflows that have increased from USD 2.5 billion in 2000–01 to USD 50 billion in 2019–20.
- Growth in Preference for Minimally Invasive Treatment - Minimally invasive operations made up 11.1% of these procedures in 2017 and were assisted by robotics in 2.5% of them; these percentages increased to 11.2% and 2.9%, respectively, in 2018.
- Upsurge in Consumption of Alcohol - By 2024, it was predicted that India's alcohol consumption would rise to roughly 7 billion litres from approximately 4 billion litres as it was in 2020.
Challenges
- Stringent Government Regulations
- Risk Associated with Cardiac Ablation - Cardiac Ablation is estimated to cause various complication owing to the procedure. It may lead to bleeding and may also cause infection on the area where catheter was inserted. Moreover, it could also damage the blood vessel or heart valve. Sometimes patients also suffer from heart-attack and stroke. However, in rare cases it might cause death. Hence owing to all these complications the cardiac ablation market is expected to hinder over the forecast period.
- High Cost of the Treatment
Cardiac Ablation Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
13.7% |
|
Base Year Market Size (2024) |
USD 3.86 billion |
|
Forecast Year Market Size (2037) |
USD 20.49 billion |
|
Regional Scope |
|
Cardiac Ablation Segmentation
Technology (Radiofrequency, Electrical, Cryoablation, Ultrasound, Microwave)
The global cardiac ablation market is segmented and analyzed for demand and supply by technology into radiofrequency, electrical, cryoablation, ultrasound, and microwave. Out of which, the radiofrequency segment is anticipated to garner the highest revenue by the end of 2037. The growth of the cardiac ablation market can be attributed to the growing number of cardiovascular diseases all around the globe. According to the World Health Organization, the main cause of death worldwide is cardiovascular disease (CVD). In 2019, 32% of all fatalities worldwide were attributable to CVDs, killing an estimated 17.9 million individuals. Heart attacks and strokes were to blame for 85% of these deaths. Radiofrequency has been used to create percutaneous left heart access and has been proven effective at reanalyzing the central and peripheral arteries. Moreover, it is known to be safe and effective in treating heart disease. Moreover, the ultrasound segment is anticipated to grow significantly over the forecast period, backed by growing demand for ultrasound devices.
Application (Cardiac Arrhythmia, Atrial Fibrillation, Tachycardia, Open Surgery)
The global cardiac ablation market is also segmented and analyzed for demand and supply by application into cardiac arrhythmia, atrial fibrillation, tachycardia, and open surgery. Amongst these segments, the atrial fibrillation segment is anticipated to grow significantly over the forecast period, backed by its growing frequency. Moreover, the growing consumption of alcohol and smoking is also estimated to boost the frequency of atrial fibrillation. Additionally, growing intake of caffeine is also anticipated to drive the growth of the segment in the cardiac ablation market. Also, atrial fibrillation risk is higher in people with specific chronic illnesses such as diabetes, metabolic syndrome, chronic renal disease, lung disease, or sleep apnea. Blood could build up and form clots in the upper chambers of the heart (atria) as a result of the disorderly cardiac rhythm in atrial fibrillation. A stroke may result from a blood clot in the left atrium of the heart that escapes and travels to the brain. As a person ages, the risk of stroke from atrial fibrillation increases. Hence, the treatment for atrial fibrillation is necessary. Further, this is estimated to boost the demand for effective cardiac rhythm management. Therefore, owing to the growth in this segment, the market is expected to grow further.
Our in-depth analysis of the global cardiac ablation market includes the following segments:
|
By Technology |
|
|
By Product |
|
|
By Application |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Cardiac Ablation Industry - Regional Synopsis
North American Market Forecast
The North American cardiac ablation market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037, backed by the presence of key pharmaceutical equipment companies, along with rise in number of clinical trials. Moreover, the prevalence of heart disease is also high in this region which is also estimated to boost the growth of the cardiac ablation market in this region. Most prevalent form of heart disease, coronary heart disease (CHD), claims the lives of over 382,820 people each year in United States. Almost 805,000 people experience a heart attack each year. 605,000 of these result in a first-time heart attack, while 200,000 are caused by previous heart attacks. Further, there has been growing investment made in the development of cardiac ablators and rise in technological advancement, which would further enhance productivity which would also boost the cardiac ablation market growth in this region.
APAC Market Statistics
The Asia Pacific cardiac ablation market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market in this region can be attributed to the growing geriatric population who are prone to cardiovascular disease. However, adults as well as young people in this region are estimated to diagnose with cardiovascular disease. Although, it has less than 20% of the global population, according to estimates from the Indian Heart Association, India is responsible for over 60% of the burden of heart disease worldwide. This may be attributed to a genetic susceptibility to metabolic dysregulation and cardiomyopathy, as well as a recent change in modifiable risk factors towards increased consumption of red meat, saturated fats, and trans fats, junk foods, and higher levels of stress. Hence, the adoption of cardiovascular disease treatment is estimated to increase in this region, further boosting the market growth. Moreover, there has been a rise in manufacturers of ablation in this region, which is estimated to influence the growth of the cardiac ablation market.
Companies Dominating the Cardiac Ablation Landscape
- Medtronic
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AngioDynamics
- Atricure, Inc.
- Alcon
- Boston Scientific Corporation
- Olympus Corporation
- CONMED Corporation
- Medical Device Business Services, Inc.
- BIOTRONIK SE & Co KG
- Biosense Webster, Inc.
Recent Developments
-
Medtronic, announced the signing of a formal agreement to purchase Affera, Inc., a privately held medical technology business situated in the Boston region. For the treatment of patients with cardiac arrhythmias (irregular heartbeats) such atrial fibrillation, Affera develops and produces catheter-based cardiac ablation technologies, such as a unique localized pulsed field ablation solution (AF).
-
Biosense Webster, Inc., a subsidiary of Johnson & Johnson MedTech, announced the availability of the OCTARAY Mapping Catheter with TRUEref Technology, which is driven by the CARTO 3 Version 7 System. Atrial fibrillation and other cardiac arrhythmias were produced using the OCTARAY Mapping Catheter (AFib).
- Report ID: 4773
- Published Date: May 08, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Cardiac Ablation Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
